Evaluation of HER3 Expression as a Predictive Biomarker for Anti-EGFR Therapy in RAS Wild-Type Unresectable Advanced or Recurrent Colorectal Cancer

Evaluation of HER3 Expression as a Predictive Biomarker for Anti-EGFR Therapy in RAS Wild-Type Unresectable Advanced or Recurrent Colorectal Cancer - HER3 significance in advanced CRC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061106

Enrollment

790

Registered

2026-03-31

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who consented to participate in an ancillary study of the PARADIGM trial 2)Patients who enrolled in the PARADIGM trial between May 2015 and June 2017

Exclusion criteria

Exclusion criteria: 1) Cases excluded from the analysis in an ancillary study of the PARADIGM trial

Design outcomes

Primary

Measure	Time frame
Association between overall survival (OS) and HER3 (ERBB3) expression levels	—

Secondary

Measure	Time frame
Association between progression-free survival (PFS) and HER3 (ERBB3) expression levels Association between objective response rate (ORR) and HER3 (ERBB3) expression levels Association between disease control rate (DCR) and HER3 (ERBB3) expression levels	—

Countries

Japan

Contacts

Public ContactKazumasa Yamamoto

National Cancer Center Hospital East Department of Gastroenterology and Gastrointestinal Oncology

kayamam6@east.ncc.go.jp04-7133-1111

Outcome results